Rosetta Biosoftware Announces the Syllego System Version 3.5 with Support for Copy Number Variation

March 16, 2009 08:00 AM Eastern Daylight Time
Rosetta Biosoftware Announces the Syllego System Version 3.5 with Support for Copy Number Variation
New Software Release Mitigates Data Challenges, Improves Research Productivity for Integrative Genomic Studies
Cambridge Healthtech Institute's Comprehending Copy Number Variation Conference
SEATTLE--(BUSINESS WIRE)--Rosetta Biosoftware, a global leader in life science informatics solutions, today announced the availability of copy number variation (CNV) data management and analysis capabilities in the latest release of the Syllego™ system. Syllego version 3.5 also offers scientists the ability to co-analyze gene expression (GE), CNV and genotyping data through enhanced statistical and visualization features and a data exchange gateway to the Rosetta Resolver® system. The new software release adds CNV to the Syllego system's current support for genome-wide association (GWA), linkage and eQTL studies, improving research productivity and expanding the software system's effectiveness in addressing the informatics challenges of scientists engaged in integrative genomic research.
In recent years, the existence of copy number as a common form of genetic variation, and its ability to influence phenotype, have been well established. Copy number variation is the subject of an increasing set of investigations to determine the extent and nature of its role in complex diseases. These studies look beyond single nucleotide polymorphisms (SNPs) in an effort to create a more complete picture of the associations between genetic variation and disease-related phenotypes. The need to manage, integrate and derive complicated dependencies between diverse data types – copy number, SNP, gene expression and phenotypic – from both public and proprietary sources is central to the success of this research. Syllego version 3.5 mitigates these challenges by providing
a common repository for commercial and custom copy number data and associated phenotypic data
a platform to integrate public copy number variation, genome data with proprietary data and analyze the composite data set
integrative analysis of genotyping, copy number variation and gene expression datasets
an open analysis platform that allows researchers to instantly use new public or proprietary analysis methods in easy-to-use interfaces
geneticists, biologists, informaticians and IT specialists with a single software solution to perform data management, data analysis, store results, and visualize results
"With the addition of CNV support, scientists can now use the Syllego system to interrogate complex data and find answers they've not been able to find before," said Yelena Shevelenko, General Manager, Rosetta Biosoftware. "We continue to execute on our strategy to deliver innovative technology to life scientists as they transform our understanding of biology and shape a new future for healthcare."
The Syllego system version 3.5 will be showcased at Cambridge Healthtech Institute's Comprehending Copy Number Variation Conference in San Diego on March 16, 2009; and during a Webinar hosted by Rosetta Biosoftware on March 25, 2009 at 9:00 AM Pacific Daylight Time. For more information, visit www.rosettabio.com/company/events.
About the Syllego System
The Syllego system is Rosetta Biosoftware’s practical solution for genetic data management and analysis. The Syllego system includes the Affymetrix GeneChip®-compatible designation and is part of the Illumina® Connect program. For more information on the Syllego system, please visit www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc. More information about Rosetta Biosoftware is available at www.rosettabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2008, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver, Resolver, Elucidator, and Syllego are trademarks of Rosetta Inpharmatics LLC.